Caenorhabditis elegans
- CRISPR-Cas9 human gene replacement and phenomic characterization in Caenorhabditis elegans to understand the functional conservation of human genes and decipher variants of uncertain significance
Summary: Here, we provide a CRISPR-Cas9 human gene replacement and phenomic characterization strategy to directly replace Caenorhabditis elegans genes with their human orthologs for disease variant modeling and therapeutic screening.
- Modelling brain dopamine-serotonin vesicular transport disease in Caenorhabditis elegans
Summary: The first Caenorhabditis elegans model to study brain dopamine-serotonin vesicular transport disease, demonstrating impairment of pharyngeal pumping and grazing phenotypes.
- Genetic and cellular sensitivity of Caenorhabditis elegans to the chemotherapeutic agent cisplatin
Summary: Caenorhabditis elegans is a valuable model to identify genetic factors influencing the animal response to the widely used chemotherapeutic agent cisplatin.
- Rescue of ATXN3 neuronal toxicity in Caenorhabditis elegans by chemical modification of endoplasmic reticulum stress
Summary: We introduce a novel C. elegans model for Machado–Joseph disease for use in preclinical drug discovery and identified guanabenz as a potent neuroprotective molecule.